Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2767-2776

  Ilett, Elizabeth J ^a   Bárcena, Montserrat ^e   Errington Mais, Fiona ^a   Griffin, Stephen ^a   Harrington, Kevin J ^b   Pandha, Hardev S ^c   Coffey, Matthew ^d   Selby, Peter J ^a   Limpens, Ronald W A L ^e   Mommaas, Mieke ^e   Hoeben, Rob C ^e   Vile, Richard G ^f   Melcher, Alan A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d ONCOLYTICS BIOTECH INC   (Canada)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JUNCTIONAL ADHESION MOLECULE A; ONCOLYTIC VIRUS; SIALIC ACID;

ARTICLE; CELL DEATH; CELL MATURATION; COCULTURE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ELECTRON MICROSCOPY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MELANOMA; MELANOMA CELL; ONCOLYTIC VIROTHERAPY; PHAGOCYTOSIS; PRIORITY JOURNAL; REOVIRUS; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; VIRUS ENTRY; VIRUS LOAD; VIRUS NEUTRALIZATION;

ANTIBODIES, NEUTRALIZING; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DRUG CARRIERS; ENDOCYTOSIS; HUMANS; MELANOMA; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; REOVIRIDAE; SKIN NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME; VIRAL LOAD; VIRUS INTERNALIZATION;

EID: 79955520856     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3266     Document Type: Article

References (35)

1. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009;9:64-71.
2. Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H. Reovirus: viral therapy for cancer 'as nature intended'. Clin Oncol (R Coll Radiol) 2008;20:548-54.
3. Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene 2005;24:7802-16. (Pubitemid 41670681)
4. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005;5:965-76. (Pubitemid 41766784)
5. Benencia F, Courreges MC, Fraser NW, Coukos G. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol Ther 2008;7:1194-205.
6. Grunewald K, Lyons J, Frohlich A, Feichtinger H, Weger RA, Schwab G, et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43:1037-41. (Pubitemid 19158034)
7. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, Van Der Eb AJ, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987;327:293-7.
8. Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, et al. Activated ras oncogenes in human thyroid cancers. Cancer Res 1988;48:4459-63.
9. Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, Wagenaar SS, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988;48:5738-41.
10. Needleman SW, Kraus MH, Srivastava SK, Levine PH, Aaronson SA. High frequency of N-ras activation in acute myelogenous leukemia. Blood 1986;67:753-7. (Pubitemid 16130268)
11. Adams DJ, Ridinger DN, Spendlove RS, Barnett BB. Protamine precipitation of two reovirus particle types from polluted waters. Appl Environ Microbiol 1982;44:589-96. (Pubitemid 12065614)
12. Minuk GY, Paul RW, Lee PW. The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease. J Med Virol 1985;16:55-60. (Pubitemid 15098388)
13. Tai JH, Williams JV, Edwards KM, Wright PF, Crowe JE, Jr, Dermody TS. Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee. J Infect Dis 2005;191:1221-4.
14. White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene therapy 2008;15:911-20.
15. Tsai V, Johnson DE, Rahman A, Wen SF, LaFace D, Philopena J, et al. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin Cancer Res 2004;10: 7199-206. (Pubitemid 39487706)
16. Chen Y, Yu DC, Charlton D, Henderson DR. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum Gene Ther 2000;11:1553-67. (Pubitemid 30670607)
17. Qiao J, Kottke T, Willmon C, Galivo F, Wongthida P, Diaz RM, et al. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 2008;14:37-44.
18. Iankov ID, Blechacz B, Liu C, Schmeckpeper JD, Tarara JE, Federspiel MJ, et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 2007; 15:114-22. (Pubitemid 46043656)
19. Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD, et al. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 2007;15:123-30. (Pubitemid 46043657)
20. Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008;180:6018-26.
21. Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther 2009;16:689-99.
22. West E, Morgan R, Scott K, Merrick A, Lubenko A, Pawson D, et al. Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery. J Immunother 2009;32:66-78.
23. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78. (Pubitemid 37324571)
24. Barton ES, Forrest JC, Connolly JL, Chappell JD, Liu Y, Schnell FJ, et al. Junction adhesion molecule is a receptor for reovirus. Cell 2001;104:441-51. (Pubitemid 32206464)
25. Paul RW, Choi AH, Lee PW. The alpha-anomeric form of sialic acid is the minimal receptor determinant recognized by reovirus. Virology 1989;172:382-5. (Pubitemid 19221468)
26. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 2005;298:315-22. (Pubitemid 40910735)
27. Rappocciolo G, Jenkins FJ, Hensler HR, Piazza P, Jais M, Borowski L, et al. DC-SIGN is a receptor for human herpesvirus 8 on dendritic cells and macrophages. J Immunol 2006;176:1741-9. (Pubitemid 43134319)
28. Lozach PY, Burleigh L, Staropoli I, Navarro-Sanchez E, Harriague J, Virelizier JL, et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J Biol Chem 2005;280:23698-708. (Pubitemid 40884852)
29. de Witte L, Abt M, Schneider-Schaulies S, van Kooyk Y, Geijtenbeek TB. Measles virus targets DC-SIGN to enhance dendritic cell infection. J Virol 2006;80:3477-86.
30. Halary F, Amara A, Lortat-Jacob H, Messerle M, Delaunay T, Houles C, et al. Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection. Immunity 2002;17:653-64. (Pubitemid 35351510)
31. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000;100:587-97.
32. Vicari AP, Caux C, Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 2002;12:33-42. (Pubitemid 34087896)
33. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colonystimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27:5763-71.
34. Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther 2008;15:1257-70.
35. Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RS, Harrington KJ, et al. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol 2009;183:4312-21.